--- title: "Pre-market hot trades in US stocks: Livewire pre-market down 8.52%; BioAge Labs pre-market up 8.41%" type: "News" locale: "en" url: "https://longbridge.com/en/news/294669027.md" description: "Livewire pre-market down 8.52%; BioAge Labs pre-market up 8.41%; AiRWA pre-market up 256.00%; Nature's Way pre-market up 135.13%; Megan pre-market up 60.05%" datetime: "2026-08-03T09:18:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294669027.md) - [en](https://longbridge.com/en/news/294669027.md) - [zh-HK](https://longbridge.com/zh-HK/news/294669027.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Livewire pre-market down 8.52%; BioAge Labs pre-market up 8.41% **Pre-market Hot Trades in US Stocks** Livewire is down 8.52% in pre-market trading. Based on recent key news: 1. On July 29, LiveWire Group CEO Karim Donnez sold 230,557 shares of common stock. The average sale price was $2.33 per share, leading to a decline in market confidence in the company's management and a corresponding drop in stock price. 2. On July 31, LiveWire Group released the above sale information through the EDGAR system, further exacerbating negative market sentiment and raising investor concerns about the company's future development. 3. There have been no other significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. BioAge Labs is up 8.41% in pre-market trading. Based on recent key news: 1. On August 1, Roth MKM analyst Adam Walsh maintained a buy rating on BioAge Labs with a target price of $25. Jefferies also maintained a buy rating with a target price of $21. These positive analyst ratings have driven the stock price up. 2. On August 1, BioAge Labs shifted focus to ophthalmic indications such as DME and GA, providing a clearer biological basis and recent concept validation milestones. Although the target price was lowered to $21, analysts believe the current risk-reward remains attractive, supporting the stock price increase. 3. On August 1, BioAge Labs plans to release Phase II data for BGE-102 and conduct ophthalmic research, with sufficient funds to support another concept validation trial. Analysts believe the risk-reward is reasonable, maintaining a buy rating with high expected return potential. The healthcare sector has performed strongly recently, with significant capital inflows. **Top Gainers in Pre-market US Stocks** AiRWA is up 256.00% in pre-market trading. Based on recent key news: 1. On July 31, AiRWA announced its plan to launch the AiRWA Exchange, focusing on tokenized trading of US stocks. This innovative move combines AI-driven enterprise services and intellectual property licensing, significantly boosting the company's stock price. 2. On July 30, the US Securities and Exchange Commission issued a statement confirming AiRWA's expansion and acquisition activities, further enhancing market confidence in its future growth. 3. On July 31, despite facing challenges such as declining revenue, negative earnings, and high debt, the company's diversified technology and financial strategies continue to attract investor attention, leading to a significant rise in stock price. Market interest in innovation and tokenized trading has increased. Nature's Way is up 135.13% in pre-market trading. Based on recent key news: 1. On August 1, Nature's Way released important information through the EDGAR system, possibly involving financial or strategic adjustments, leading to a significant rise in stock price. This information was disclosed on the company's official website, increasing market confidence in its future development 2. On August 3rd, the overall optimistic sentiment in the biopharmaceutical industry drove the rise of related stocks. Although other companies like Addentax Group and Apnimed Inc experienced declines in pre-market trading, the increase in Nature's Way Pharmaceuticals reflects investors' recognition of its unique advantages. 3. No other significant news recently. The biopharmaceutical industry has performed strongly lately, with noticeable capital inflows. Megan rose 60.05% in pre-market trading. There is no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no\_news ### Related Stocks - [LVWR.US](https://longbridge.com/en/quote/LVWR.US.md) - [BIOA.US](https://longbridge.com/en/quote/BIOA.US.md) - [YYAI.US](https://longbridge.com/en/quote/YYAI.US.md) - [UPC.US](https://longbridge.com/en/quote/UPC.US.md) - [MGN.US](https://longbridge.com/en/quote/MGN.US.md) ## Related News & Research - [LiveWire files Form 3 for Head of Human Resources & Systems Erica Case](https://longbridge.com/en/news/296649256.md) - [S4 Honcho™ Begins U.S. Dealer Deliveries as LiveWire Names Nationwide Giveaway Winner | LVWR Stock News](https://longbridge.com/en/news/296609703.md) - [Harley Davidson (HOG) Could Be 5% Overvalued After Its Recent Rebound](https://longbridge.com/en/news/296943438.md) - [TechDigital Labs Announces Integrated Marketing and Technology Service Model.](https://longbridge.com/en/news/296957889.md) - [Nattaro Labs Q2 FY26 net loss narrows to SEK 648,000; revenue more than doubles to SEK 2.06 million](https://longbridge.com/en/news/296997074.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**